Literature DB >> 16552633

Gn-RH antagonists in intrauterine insemination: the weekend-free protocol.

Roberto Matorras1, Olga Ramón, Antonia Expósito, Beatriz Corcóstegui, Iratxe Ocerin, Sandra Gonzalez-Lopera, Francisco J Rodríguez-Escudero.   

Abstract

OBJECTIVE: To compare the results of intrauterine insemination (IUI) when GnRH antagonist was added-to avoid IUI on weekend-with those obtained with the standard IUI protocol. STUDY
DESIGN: In an IUI program under ovarian stimulation with gonadotropins when one or more follicles of 15-16 mm were seen, if it was not possible for logistic reasons (weekend) to perform the insemination 72 h later, GnRH antagonist was administered until human chorionic gonadotropin (hCG) administration. The IUI was performed on Monday. We compared the results of this IUI "weekend-free'' group with our results in standard IUI cycles, where IUI was performed 36-38 h after reaching optimal follicular growth.
RESULTS: Both groups were comparable regarding the main demographic parameters, except for higher estradiol levels, due to the prolonging ovarian stimulation. The per cycle pregnancy rate (PR) were very similar in both groups: 15.7% in the weekend-free IUI versus 16.5% in standard IUI. The multiple pregnancy rate and the hyperstimulation rate were also similar. A non-significant trend to higher high-order multiple pregnancy was observed in the weekend-free IUI.
CONCLUSIONS: In IUI cycles under ovarian suprastimulation with gonadotrophins, the use of GnRH antagonist allows the manipulation of the follicular development in such a way that it is possible to avoid inseminations on the weekends, without apparently reducing the PR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552633      PMCID: PMC3454901          DOI: 10.1007/s10815-005-9019-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  14 in total

1.  Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoa.

Authors:  R Matorras; V Recio; B Corcóstegui; F J Rodríguez-Escudero
Journal:  Hum Reprod       Date:  2000-06       Impact factor: 6.918

2.  Converting an IVF cycle to IUI in low responders with at least 2 follicles.

Authors:  Roberto Matorras; Beatriz Corcóstegui; Rosario Mendoza; Olga Ramón; Victoria Aparicio; Maria Teresa Uriarte; Francisco J Rodríguez-Escudero
Journal:  J Reprod Med       Date:  2003-10       Impact factor: 0.142

3.  Addition of gonadotrophin-releasing hormone agonist and/or two inseminations with husband's sperm do not improve the pregnancy rate in superovulated cycles.

Authors:  P O Karlström; T Bergh; O Lundkvist
Journal:  Acta Obstet Gynecol Scand       Date:  2000-01       Impact factor: 3.636

4.  Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

Authors:  F Olivennes; J Belaisch-Allart; J C Emperaire; H Dechaud; S Alvarez; L Moreau; B Nicollet; J R Zorn; P Bouchard; R Frydman
Journal:  Fertil Steril       Date:  2000-02       Impact factor: 7.329

5.  Sperm morphology analysis (strict criteria) in male infertility is not a prognostic factor in intrauterine insemination with husband's sperm.

Authors:  R Matorras; B Corcóstegui; C Perez; M Mandiola; R Mendoza; F J Rodríguez-Escudero
Journal:  Fertil Steril       Date:  1995-03       Impact factor: 7.329

6.  Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles.

Authors:  G Ragni; P Maggioni; E Guermandi; A Testa; E Baroni; M Colombo; P G Crosignani
Journal:  Fertil Steril       Date:  1999-10       Impact factor: 7.329

Review 7.  The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.

Authors:  K Diedrich; M Ludwig; R E Felberbaum
Journal:  Semin Reprod Med       Date:  2001-09       Impact factor: 1.303

8.  Does increasing frequency of intrauterine insemination improve pregnancy rates significantly during superovulation cycles?

Authors:  M X Ransom; M B Blotner; M Bohrer; G Corsan; E Kemmann
Journal:  Fertil Steril       Date:  1994-02       Impact factor: 7.329

9.  Late low-dose pure follicle stimulating hormone for ovarian stimulation in intra-uterine insemination cycles.

Authors:  J Balasch; J L Ballescá; C Pimentel; M Creus; F Fábregues; J A Vanrell
Journal:  Hum Reprod       Date:  1994-10       Impact factor: 6.918

10.  Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH.

Authors:  R Matorras; T Diaz; B Corcostegui; O Ramón; J I Pijoan; F J Rodriguez-Escudero
Journal:  Hum Reprod       Date:  2002-08       Impact factor: 6.918

View more
  4 in total

1.  Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine insemination.

Authors:  Ramazan Dansuk; Ali Ihsan Gonenc; Sinem Sudolmus; Oguz Yucel; Osman Sevket; Nadiye Köroğlu
Journal:  Singapore Med J       Date:  2015-06       Impact factor: 1.858

Review 2.  Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.

Authors:  Astrid Ep Cantineau; Anouk Gh Rutten; Ben J Cohlen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-05

Review 3.  Effectiveness of GnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: a meta-analysis.

Authors:  Shan Luo; Shangwei Li; Song Jin; Ya Li; Yaoyao Zhang
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

4.  GnRH antagonist administration to postpone a weekend intrauterine insemination: a large cohort study from a public center.

Authors:  J Gobernado; C Alvarez-Colomo; L Rodriguez-Tabernero; L Barrero; J M F Fernández-Gómez; J Schneider
Journal:  Reprod Biol Endocrinol       Date:  2016-09-02       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.